Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 415 across all filing types
Latest filing 2010-11-17 Environmental & Social …
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Darmkrebs-Fruherkennungstest fur zuhause eingefuhrt
Environmental & Social Information Classification · 99% confidence The document is a press release dated November 17, 2010, announcing the introduction of a new product (a colorectal cancer screening test) by NanoRepro AG. It details the product, its benefits, target audience, and pricing. The structure, including the 'News Details' header, date, company name, keywords, and the concluding section mentioning DGAP distribution services, strongly indicates a general corporate announcement or press release regarding a business event (product launch). This type of announcement, which is not a formal financial report (like 10-K, IR, ER) or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV), best fits the general 'Regulatory Filings' or 'Report Publication Announcement' categories. Since it is announcing a business event/product launch rather than the publication of a formal financial report, and it doesn't fit any other specific financial disclosure category, it is classified as a general regulatory announcement, which aligns best with RNS (Regulatory Filings) as a broad category for non-standard disclosures, or potentially RPA if it were announcing the release of a different report. Given the content is a news announcement about a product launch, RNS is the most appropriate fallback for a general corporate news item not covered elsewhere.
2010-11-17 German
NanoRepro AG erreicht Vertriebsdurchbruch und unterzeichnet Absichtserklarung uber den Verkauf von bis zu 36 Millionen Schnelltests
Regulatory Filings Classification · 95% confidence The document is a short news release dated November 12, 2010, announcing that NanoRepro AG signed a Letter of Intent ('Absichtserklärung') for the sale of up to 36 million rapid tests to an international trading company. It details the scope of the agreement, expected timelines, and product focus. The document structure, brevity (under 5,000 characters), and the nature of the announcement (a significant business development/sales agreement) strongly suggest it is a general corporate announcement rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or an Interim Report (IR). Since it details a significant business transaction/development that isn't explicitly covered by other specific codes (like M&A, Financing, or Dividend), it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate news item, or potentially a Capital/Financing Update (CAP) if the focus was purely on the financial structure change, but here the focus is on a major sales agreement/distribution breakthrough. Given the options, RNS serves as the best general corporate news fallback for significant, non-standard announcements.
2010-11-12 German
Marburger Unternehmen stellt neuen Schwangerschaftsfruhtest beim 58. Kongress der Deutschen Gesellschaft fur Gynakologie und Geburtshilfe vor
Regulatory Filings Classification · 100% confidence The document is a short news release dated October 5, 2010, announcing the introduction of a new early pregnancy test (GraviQUICK-Frühtest) at a medical congress. It uses keywords like 'News Details', 'Corporate', 'Schlagwort(e): Produkteinführung/Produkteinführung' (Product Launch), and concludes with a standard disclaimer and a note about distribution via DGAP (a service for corporate news). Since it is an announcement about a product launch and general corporate news, and it is not a formal financial report (like 10-K or IR), nor a transcript (CT), nor a specific regulatory filing like DIRS or DIV, it best fits the general category for miscellaneous corporate announcements. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news release that doesn't fit a more specific category like ER or CAP, although 'RPA' (Report Publication Announcement) is sometimes used for announcements, this is a product launch announcement, making RNS the better fit for general news distribution.
2010-10-05 German
NanoRepro AG: Das Unternehmen weitet Apothekenvertrieb aus und gewinnt CURA-SAN als Partner
Regulatory Filings Classification · 100% confidence The document is a short news release dated September 17, 2010, announcing a new partnership between NanoRepro AG and CURA-SAN GmbH regarding the distribution of self-diagnostics products in pharmacies and medical supply stores. It contains standard corporate news elements, including a headline, details of the agreement, quotes from management, a brief 'About Us' section, and a disclaimer. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed quarterly report (IR). Since it is a general corporate announcement about a business development (a cooperation agreement) that doesn't fit into the more specific categories (like M&A, Capital Change, or Director's Dealing), it falls best under the general Regulatory Filings/Announcements category, which is RNS, as per the definition of RNS being the fallback for miscellaneous filings.
2010-09-17 German
NanoRepro AG: Hochkaratiger Neuzugang fur den strategischen Beirat
Board/Management Information Classification · 100% confidence The document is a corporate news release dated September 15, 2010, announcing a strategic addition to the company's advisory board (Michael Joachim Tillmann). The key content revolves around personnel changes, strategic direction (internationalization), and the involvement of a new strategic investor who also plans to run for the supervisory board. This type of announcement, detailing changes in senior management or board composition, directly aligns with the definition of 'Board/Management Information' (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific management/governance event.
2010-09-15 German
NanoRepro AG: NanoRepro AG macht mit der Einfuhrung vom Fruchtbarkeitstrio Kinderwunsche wahr
Regulatory Filings Classification · 100% confidence The document is a press release dated September 8, 2010, announcing the launch of a new product trio ('Fruchtbarkeitstrio') by NanoRepro AG. It details the product features, market potential, and company strategy regarding self-diagnostics. The text ends with standard press release boilerplate, including contact information and a disclaimer, and is distributed via DGAP, which handles 'Corporate News/Finanznachrichten'. This format strongly suggests a general corporate announcement or news release rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate news item that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which often captures general news releases distributed through official channels.
2010-09-08 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.